◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Nectar Lifesciences Limited (NECLIFE) Financial History

Name: Nectar Lifesciences Limited (NECLIFE) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Nectar Lifesciences Limited (NECLIFE) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Chandigarh, India with about 111 employees. Its market capitalization is roughly ₹2 billion. In the fiscal year ended 2026-03-31, NECLIFE reported ₹0M in revenue and (₹2.9B) in net income.

Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally.

Interactive charts & full statements →

NECLIFE Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹0M	₹0M	₹16.8B	₹15.2B	—
Gross Profit	(₹0M)	₹0M	₹3.0B	₹1.9B	—
Operating Income (EBIT)	(₹291M)	(₹626M)	₹924M	(₹52M)	—
Net Income	(₹2.9B)	(₹1.1B)	₹50M	(₹242M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NECLIFE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	₹0M	₹0M	₹0M	₹50M	₹0M	—
Gross Profit	₹0M	₹0M	₹0M	₹16M	₹0M	—
Operating Income (EBIT)	(₹274M)	(₹573M)	(₹20M)	(₹5M)	(₹2M)	—
Net Income	(₹154M)	(₹679M)	₹143M	(₹3M)	(₹632M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NECLIFE Free Cash Flow History

NECLIFE Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹6.2B	₹20.5B	₹21.9B	₹21.9B	—
Total Liabilities	₹393M	₹10.9B	₹11.2B	₹11.2B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NECLIFE viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

AMBALALSA · Ambalal Sarabhai Enterprises Limited — ₹3 billion
MEDICO · Medico Remedies Limited — ₹3 billion
1349 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. — HK$3 billion
2552 · Hua Medicine (Shanghai) Ltd. — HK$2 billion
2561 · VISEN Pharmaceuticals — HK$2 billion
2633 · Jacobson Pharma Corporation Limited — HK$2 billion
DMP · Dermapharm Holding SE — €2 billion
BROOKS · Brooks Laboratories Limited — ₹2 billion

← NECCLTD All “N” companies NEDAP →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.